Inter Partes Review Proceedings
PTAB Portal
IPR Case No(s):
U.S. Patent No.
7,521,052 (Methods for Treating Interleukin-6 Related Diseases)
Patent Owner
Chugai Seiyaku Kabushiki Kaisha
Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA
§ 102 Challenge
Y
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted; Pending
U.S. Patent No.
10,744,201 (Method for Treating Rheumatoid Arthritis with a Human IL-6 Receptor Antibody and Methotrexate)
Patent Owner
Chugai Seiyaku Kabushiki Kaisha
Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA
§ 102 Challenge
Y
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted; Pending
U.S. Patent No.
8,580,264 (Subcutaneously Administered Anti-IL6 Receptor Antibody)
Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Genentech, Inc.; Hoffmann-La Roche Inc.
Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA
§ 102 Challenge
Y
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted; Pending
U.S. Patent No.
10,874,677 (Subcutaneously Administered Anti-IL6 Receptor Antibody)
Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.
Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA
§ 102 Challenge
Y
Claim Types Challenged Under § 102
Other (Drug Delivery Device)
§ 102 Challenge Instituted
Y
§ 103 challenge
Y
Claim Types Challenged Under § 103
Other (Drug Delivery Device)
§ 103 Challenge Instituted
Y
IPR Status
Instituted; Pending
U.S. Patent No.
8,580,264 (Subcutaneously Administered Anti-IL6 Receptor Antibody)
Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Genentech, Inc.; Hoffmann-La Roche Inc.
Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA
§ 102 Challenge
Y
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted; Pending
U.S. Patent No.
9,750,752 (Subcutaneously Administered Anti-IL6 Receptor Antibody)
Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.
Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, LLC; Fresenius SE & Co. KGaA
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Awaiting Institution Decision
IPR Status
Awaiting Institution Decision
U.S. Patent No.
8,580,264 (Subcutaneously Administered Anti-IL6 Receptor Antibody)
Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.; Genentech, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co. Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Awaiting Institution Decision
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Awaiting Institution Decision
IPR Status
Awaiting Institution Decision
U.S. Patent No.
10,874,677 (Subcutaneously Administered Anti-IL6 Receptor Antibody)
Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.; Genentech, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co. Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y
Claim Types Challenged Under § 102
Other (Drug Delivery Device)
§ 102 Challenge Instituted
Awaiting Institution Decision
§ 103 challenge
Y
Claim Types Challenged Under § 103
Other (Drug Delivery Device)
§ 103 Challenge Instituted
Awaiting Institution Decision
IPR Status
Awaiting Institution Decision